DNLI News

Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

Press Registration Is Now Open for the 2026 ACMG Annual Clinical Genetics Meeting

Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights